Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors

Why It Matters

The funding positions Oricell to push the first solid‑tumor CAR‑T therapy toward pivotal trials, potentially reshaping treatment options for liver cancer and setting a precedent for immunotherapy against hard‑to‑target tumors.

Key Takeaways

• Oricell raised over $110 million in pre‑IPO financing.
• Lead CAR‑T candidate Ori‑C101 targets GPC3 in liver cancer.
• Six of ten patients showed response; nine achieved disease control.
• Pipeline includes six additional cell therapies and in‑vivo CAR‑T platform.
• Investors include Vivo Capital, Qiming Venture Partners, Beijing Medical Fund.

Pulse Analysis

CAR‑T therapies have transformed blood‑cancer treatment, but solid tumors remain a frontier due to heterogeneous antigens and immunosuppressive microenvironments. Oricell’s “armored” CAR‑T design aims to breach these defenses by engineering cells that can persist and function within the hostile tumor niche. Targeting glypican‑3 (GPC3), a protein overexpressed on hepatocellular carcinoma cells, Ori‑C101 leverages this strategy to deliver a focused attack while sparing healthy tissue, a critical safety consideration for liver‑focused immunotherapies.

The $110 million pre‑IPO round, led by Vivo Capital and Qiming Venture Partners, adds to Oricell’s capital base, bringing total raised to roughly $180 million. This influx will fund expanded Phase 1/2 trials for Ori‑C101, accelerate development of its six other candidates, and support the in‑vivo CAR‑T platform that programs immune cells directly inside patients. By securing financing before a public listing, Oricell can retain strategic flexibility while signaling confidence to the market, a move that may attract further institutional interest as investors chase the next breakthrough in oncology.

If Ori‑C101 confirms its early efficacy signals in larger cohorts, it could become the first approved CAR‑T therapy for a solid tumor, prompting a wave of R&D investment across the sector. Competitors are racing to address similar challenges, but Oricell’s dual focus on armored cell constructs and novel antigen targets differentiates its pipeline. Success would not only broaden therapeutic options for liver cancer patients but also validate the broader concept of CAR‑T applicability beyond hematologic malignancies, potentially reshaping regulatory pathways and reimbursement models for next‑generation immunotherapies.